Article PDF first page preview

First page of Caffeine and its metabolites are associated with overactive bladder: evidence from multiple statistical analysis models in NHANES.

Background: To offer valuable insights into potential dietary influences on bladder health, the study investigate the relationship between urinary caffeine metabolites and Overactive bladder syndrome (OAB). Methods: The data for this investigation consisted of individuals who were 20 years old or older, obtained from the National Health and Nutrition Examination Survey (NHANES) database. To assess the correlation between urinary caffeine metabolites and OAB, logistic regression analyses were utilized. In addition, Quantile g-computation model (Qgcomp) and Bayesian kernel machine regression (BKMR) model were used to determine the combined effect of urine caffeine metabolites on OAB risk. Results: In the analyses of a dataset comprising 4,354 participants, 815 were diagnosed with OAB. After adjusting for various covariates, logistic regression analyses revealed the highest tertiles of caffeine metabolites and ln-transformed caffeine metabolites were negatively associated with OAB risk. Subsequent analyses using the Qgcomp demonstrated that an increase in the quartiles of caffeine metabolites mixture was associated with a decreased risk of developing OAB. The OR were 0.89 (95% CI: 0.81, 0.99). Moreover, such negative correlation was primarily driven by 1,3-dimethylxanthine (1,3-DMX) and 1-methylxanthine(1-MX). The BKMR model confirmed a strong inverse link between urinary caffeine metabolites and OAB. Conclusion: Our work demonstrates a strong inverse relationship between urine caffeine metabolites and the occurrence of overactive bladder (OAB). Among these metabolites, 1,3-DMX and 1-MX have the most pronounced impact on the combined effect. These findings suggest that the way caffeine is metabolized in the body could play a crucial role in the development of OAB.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.